Swiss Medica Inc. ein MUSS

Quelle: DEL LA RUE - Investment Team

Swiss Medica Inc. erforscht, entwickelt und vermarktet Medikamente auf pflanzlicher Basis. Ende 2004 gelang es dem unternehmen mit dem Schmerzlindernden Medikament "O24" einen Blockbuster rauszubringen. Der Umsatz konnte seit der Vermarktung innerhalb von einem Jahr verdoppelt werden. Neben dem drittgrößten Drug-Store in den USA "Rite Aid" kann man "O24" inzwischen in über 1.600 Geschäften erwerben. Teilweise mussten sich Händler das Produkt für Monate im Voraus sichern um einen Engpass in der Belieferung zu vermeiden. SwissMedica geht daher davon aus noch in diesem Jahr schwarze Zahlen zu schreiben.
According to David A. Bench, editor of The Research Works, Inc., Swiss Medica’s stock is “significantly undervalued... We are convinced that encouraging clinical trials and positive ‘word of mouth’ should translate into robust revenue growth within the next few quarters.

Die Aktie ist ein Muss für jeden Risikofreudigen Anleger.

8/25/2005 12:50:33 PM ET News Release Index


SWISS MEDICA ANNOUNCES INSIDER BUYING PLAN
FOR IMMEDIATE RELEASE

Stock Symbol: OTC BB: SWME
Aug 25, 2005

SWISS MEDICA ANNOUNCES INSIDER BUYING PLAN

TORONTO-Swiss Medica, Inc. (OTCBB: SWME) is pleased to announce that Swiss Medica’s senior management team and members of Swiss Medica’s Board of Directors intend to purchase on the open market, shares of the Company's publicly traded Class A common stock, based on their assessment of prevailing market prices. Whether any such purchases are made, and the number of shares purchased, will depend upon the availability of shares at acceptable market prices. All trades will comply with Swiss Medica’s insider trading policy and insiders will file Form 4s with the S.E.C. as purchases are completed.

Mr. Raghu Kilambi, Swiss Medica’s CEO commented, “At current levels, we believe our stock is undervalued. These planned open market purchases illustrate our confidence in Swiss Medica’s underlying business strategy.”

Swiss Medica Reports Early Success at Retail for PMS Escape

TORONTO--(BUSINESS WIRE)--Aug. 29, 2005--Swiss Medica, Inc. (OTCBB:SWME) today announced that just weeks after hitting U.S. retail shelves, its recently-launched PMS Escape product has been selling out in many stores.

"We are pleased to see such strong initial sales for PMS Escape," notes Wendy Kramer, Swiss Medica's Vice President. "PMS Escape went into 5,000+ retail stores in late July and, in just two weeks, there have been reorders totaling more than 25% of the initial order. PMS is one of the most common women's health problems in the U.S. and with PMS Escape, women now have a safe and clinically proven way to help them manage the mood and appetite symptoms associated with premenstrual syndrome," adds Kramer.

PMS Escape is a clinically tested, patented, all natural product to help women with premenstrual syndrome (PMS) related disturbances in mood and appetite. It is the first over the counter product available at retail to help women manage these disturbances. PMS Escape is a powdered drink mix that contains the precise amounts of carbohydrates, vitamins and minerals that work naturally with the body to raise serotonin levels, which scientists believe decrease during PMS. For retail availability, customers can go to www.pmsescape.com.

About Swiss Medica Inc.

Swiss Medica commercializes proprietary bioscience products that relieve chronic ailments. We increase our market share through focused distribution strategies in multiple sales channels. Swiss Medica's mission is to be a world leader in the commercialization of life enhancing bioscience products that improve quality of lives. Please visit our websites at www.swissmedica.com ,www.O24zone.com and www.pmsescape.com

Swiss Medica's flagship product, the O24(TM) Essential Oil Pain Neutralizer, holds US Patent #6,444,238B1. The O24(TM) pain relief solution has been used, recommended and praised for its fast-acting and long-lasting benefits by healthcare professionals and athletes in the United States, Canada and in Europe. O24 is widely available throughout the United States and Canada in leading pharmacies and other retailers. Customers can also visit www.O24zone.com, for ordering details and store locators for the nearest pharmacy.

Swiss Medica is launching the patented O24(TM) Fibromyalgia pain reliever (US Patent #6,444,238B1) over-the-counter in North American retailers in the fall of 2005. The National Fibromyalgia Association (NFA) recently awarded O24(TM) Fibromyalgia their first NFA Seal of Approval. Upwards of 11 million Americans suffer from the long-term pain associated with fibromyalgia. In a randomized double blind clinical trial, more than 90 per cent of the patients who used O24 Fibromyalgia(TM) reported mild to markedly better improvement, versus only 7 per cent who used the placebo. Customers can visit www.024zone.com for information on O24 Fibromyalgia(TM) and to order the product online.

Swiss Medica also manufactures PMS Escape(R) which holds US Patent #'s 5760014 and 5612320. PMS Escape(R) is a specially formulated group of carbohydrates, vitamins and minerals, clinically proven to reduce changes in mood and appetite that women experience during the premenstrual period. Customers can also visit: www.pmsescape.com for additional information and ordering details.

Forward-looking statements in this news release are made pursuant to the "Safe Harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including, without limitation, risks relating to the ability to close transactions being contemplated, risks related to international sales and potential foreign currency exchange fluctuations, continued acceptance of Swiss Medica's products, increased levels of competition, technological changes, dependence on intellectual property rights and other risks detailed from time to time in Swiss Medica's periodic reports filed with the United States Securities and Exchange Commission and other regulatory authorities.

Quelle: DEL LA RUE - Investment Team
www.dellarue.de
www.SwissMedica.com  

Walgreens Now Offering Swiss Medica's O24 Pain Neutralizer
Tuesday September 20, 6:00 am ET


TORONTO--(BUSINESS WIRE)--Sept. 20, 2005--Swiss Medica, Inc. (OTC BB:SWME - News) is pleased to announce that Walgreens is now offering its O24 Pain Neutralizer product nationwide.
ADVERTISEMENT


"We are pleased that Walgreens has become the newest national pharmacy chain to carry O24 Pain Neutralizer," said Thomas Quinn, Swiss Medica's Executive Vice President. "We believe this will enable millions of people who suffer daily pain to have access to our patented, effective and safe pain reliever."  

Prognosen bestärkt!

Die positiven Aussichten, noch diese Jahr schwarze Zahlen zu schreiben werden duch den regen Newsfloat bestärkt! Das erst vor gut zwei Jahren gegründete Unternehmen fuhr im ersten Geschäftshalbjahr rund 2,5 Mio USD Erlös ein. Die Prognosen wurden daher nach ablauf des ersten Halbjahres erhöht. Man geht von einem Jahresumsatz zwischen 12 - 14 Mio. USD aus. (im 3Q. 3-4 Mio. / im 4Q. 5-6 Mio / abhänging von Vertragsabschlüssen mit Einzelhandelsketten)
Die entspricht  derzeit fast der Marktkapitalisierung von 18. Mio. USD.

O24 und PMS Escape werden inzwischen im immer mehr Drugstores verkauft und bestärken laut dem DEL LA RUE - Investment Team somit die Unternehmensprognosen!

RANDOMIZED DOUBLE BLIND CLINICAL STUDY SHOWS IMPROVEMENT FOR 90% OF FIBROMYALGIA PATIENTS USING SWISS MEDICA’S O24™ PAIN RELIEF PRODUCT!

Den vollen Bericht könnt ihr im Forum von www.dellarue.de nachlesen!

SwissMedica Inc. (US87089C1045) Nachkaufen
01.10.2005

Den jüngsten Abwärtstrend von Swiss Medica. Inc, beurteilen die Experten vom "DEL LA RUE - Investment Team" als günstige Nachkaufgelegenheit.

Man gehe davon aus, dass die Zahlen für das 3. Quartal bald veröffentlicht werden und im Rahmen der Prognosen liegen. Eine starke Kursexplosion halten wir für noch zu früh. Sollten die Prognosen auch im 4. Quartal bestätigt werden, wird mit einer Kusralley gerechnet. Die Kursziele liegen dabei zwischen 0.49 und 0.65 USD.

Wir raten investierten Anlegern bei Kursen bis zu 0.27 USD Nachzukaufen.
Erste Positionen sollten bis 0.35 USD aufgebaut werden.

Ein Update wird nach der Veröffentlichung der Zahlen für das 3.Q. folgen.

TOP NEWS, das macht Investoren und Privatanleger endlich noch aufmerksammer!

Swiss Medica to Present to Institutional Investors in Europe
Tuesday October 4, 6:00 am ET

TORONTO--(BUSINESS WIRE)--Oct. 4, 2005--Swiss Medica, Inc. (OTCBB:SWME - News) today announced that Chief Executive Officer, Raghu Kilambi will be making presentations to institutional investors on Swiss Medica and speaking at biotech investment conferences between October 4 and October 12th in Zurich, Cadaques (Spain), Paris, Brussels and London.

ADVERTISEMENT
Mr. Kilambi will present Swiss Medica on October 4-5th at the 5th Annual Biotech in Europe Investor Forum in Zurich, co-sponsored by Sachs Associates and Bloomberg LLP. In addition, Mr. Kilambi will present Swiss Medica on October 7-8th, 2005 at the invitation only Theime Small Cap Conference in Spain. The Thieme small cap conference showcases 6 carefully selected companies the Nanotechnology, Biotech and Energy fields.

Investors and analysts can view Swiss Medica's latest corporate and investor brochure at www.swissmedica.com.

Quelle: www.dellarue.de  

Global Biotech Daily vom 05.10.2005


Spannend könnte es in dieser Woche noch bei SWISS MEDICA werden, die sich auf Europa-Tour befinden und sich dort institutionellen Investoren präsentieren. Die Gesellschaft wird auf verschiedenen Konferenzen in Zürich, Cadaques, Paris, Brüssel und London vertreten sein und sein Geschäftsmodell vorstellen. Erste Station wird das 5. Jährliche Biotech in Europa Investor Forum in Zürich sein, das gestern begonnen hat und heute zu Ende geht. Kommenden Freitag und Samstag gastiert SWISS MEDICA im spanischen Cadaques bei der Thieme Small Cap Conference, auf der sich insgesamt 6 Unternehmen aus den Bereichen Nanotechnologie, Biotechnologie und Energie vorstellen. Gut möglich, dass sich im Anschluss an die Präsentationen auch im Kurs endlich wieder etwas tut, gestern ging es bereits 7 ½% auf USD 0.21 nach oben!

- Swiss Medica launched PMS Escape in the United States and has distribution in over 5,000 pharmacy outlets. PMS Escape is the first patented, over-the-counter and clinically proven product to deal with the mood and appetite symptoms related to pre-menstrual syndrome. PMS Escape will be launched in Canada in the fourth quarter and will continue to get increased USA distribution.

- O24 Fibromyalgia continues to gain pre-retail excitement as the first clinically tested product specifically for Fibromyalgia. The National Fibromyalgia Association, based in California, has given O24 Fibromyalgia its first and only Seal of Approval. O24 Fibromyalgia will be available nationally in the United States and Canada during the fourth quarter of 2005.

"We continue to be optimistic about Swiss Medica's growth prospects given our three patented, clinically tested chronic ailment products will be available nationally in the United States and Canada during this fourth quarter ending December 31, 2005", said Mr. Kilambi. "However, due to delays in launching new products noted above and to be conservative, we are lowering our revenue guidance for 2005 and the fourth quarter ending December 31, 2005. For the three months ending December 31, 2005, Swiss Medica expects net revenues in excess of US$2 million. That would translate to fiscal 2005 revenues in excess of US$6.3 million. Despite the lower 2005 revenues, our strong gross margins should allow Swiss Medica to report positive EBITDA for the fourth quarter ending December 31st."

Swiss Medica defines EBITDA as earnings before interest and financing fees, taxes, depreciation, amortization, and other non-cash charges. Full second quarter results, for the period ending 30 September 2005, will be included in the Company's 10-Q, which will be filed with the U.S. Securities and Exchange Commission by November 15th.

About Swiss Medica, Inc.

Swiss Medica commercializes proprietary bioscience products that relieve chronic ailments. We increase our market share through focused distribution strategies in multiple sales channels. Swiss Medica's mission is to be a world leader in the commercialization of life enhancing bioscience products that improve quality of lives. Please visit our websites at www.swissmedica.com ,www.O24zone.com and www.pmsescape.com.

Swiss Medica's flagship product, the O24 Essential Oil Pain Neutralizer, holds US Patent #6,444,238B1. The O24 pain relief solution has been used, recommended and praised for its fast-acting and long-lasting benefits by healthcare professionals and athletes in the United States, Canada and in Europe. O24 is widely available throughout the United States and Canada in leading pharmacies and other retailers. Customers can also visit www.O24zone.com, for ordering details and store locators for the nearest pharmacy.

Swiss Medica is launching the patented O24 Fibromyalgia pain reliever (US Patent #6,444,238B1) over-the-counter in North American retailers in the fall of 2005. The National Fibromyalgia Association (NFA) recently awarded O24 Fibromyalgia their first NFA Seal of Approval. Upwards of 11 million Americans suffer from the long-term pain associated with fibromyalgia. In a randomized double blind clinical trial, more than 90 per cent of the patients who used O24 Fibromyalgia reported mild to markedly better improvement, versus only 7 per cent who used the placebo. Customers can visit www.024zone.com for information on O24 Fibromyalgia and to order the product online.

Swiss Medica also manufactures PMS Escape® which holds US Patent #'s 5760014 and 5612320. PMS Escape® is a specially formulated group of carbohydrates, vitamins and minerals, clinically proven to reduce changes in mood and appetite that women experience during the premenstrual period. Customers can also visit: www.pmsescape.com for additional information and ordering details.

Forward-looking statements in this news release are made pursuant to the "Safe Harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including, without limitation, risks relating to the ability to close transactions being contemplated, risks related to international sales and purchases and potential foreign currency exchange fluctuations, continued acceptance of Swiss Medica's products, increased levels of competition, technological changes, dependence on intellectual property rights and other risks detailed from time to time in Swiss Medica's periodic reports filed with the United States Securities and Exchange Commission and other regulatory authorities.

Swiss Medica, Inc. (OTC Bulletin Board:SWME - News)

SwissMedica Inc. (US87089C1045) Ein MUSS!
22.10.2005

Swiss Medica Inc. veröffentlichte am 19. Oktober die Geschäftszahlen zum 3. Quartal 2005.

Mit einem Umsatzwachstum von 28% auf 1.77 Mil. USD gegenüber 1.38 Millionen USD im 2. Quartal 2005, lag der Umsatz deutlich unter den Erwartungen von ca. 3 Millionen USD.

Anders als erwartet, konnte der Verkauf von PMS Escape und O24 Fibromyalgia in Kanada erst im Oktober und nicht wie geplant im August beginnen. Hinzu konnten zahlreiche amerikanische O24 Fibromyalgia Aufträge nicht vor dem 30. September verwirklicht werden.

Raghue Kilambi, CEO, teile jedoch ebenfalls mit, dass der Verkauf in Kanada und Amerika bereits im Oktober begonnen hat. Mittlerweile wird O24 Fibromyalgia in über 5.000 Geschäften angeboten. Bis zum Jahresende soll sich die Anzahl der Geschäfte auf 10.000 verdoppelt haben. Der CEO erwartet für das 4. Quartal einen Umsatz von 2 Millionen USD und hofft auf ein positives EBITDA.

Die Experten vom " DEL LA RUE – Investment Team“ halten Swiss Medica Inc. weiterhin für überdurchschnittlich lukrativ. Man geht davon aus, dass sich der Umsatz in 2006 weiter positive entwickelt und ein Jahresumsatz zwischen 12 und 15 Millionen realistisch erscheint. Angesichtes dessen ist die Swiss Medica Inc. bei einem Kurs von momentan 0.14 USD deutlich unterbewertet und nach Meinungen des Investment –Teams ein Muss für ihre Anleger.

SwissMedica gründete eine SwissMedica Deutschland GmbH! Offizielle Nachrichten wurden noch nicht veröffentlicht! Zu erreichen ist SwissMedica Deutschland GmbH unter www.SwissMedica.de!!!

Swiss Medica Recognized as 2005 Company of the Year by Arthritis Foundation

TORONTO--(BUSINESS WIRE)--Nov. 28, 2005--Swiss Medica, Inc. (OTCBB:SWME) today announced that it has been awarded the Arthritis Foundation's (Northern California Chapter) prestigious 2005 Corporate Award. Grant Johnson, President and COO of Swiss Medica, along with Richard Weise, the inventor of O24, will be in attendance to accept the award on December 7, 2005, at the Annual Meeting of the Northern California Chapter of the Arthritis Foundation in San Francisco.

The award singles out Swiss Medica from a field of potential corporate candidates for the honor. Swiss Medica received this designation because it was determined that the Company has done more to assist the Foundation in its mission to advance its causes than any other contender.

In September 2005, Swiss Medica was Presenting Sponsor for the Arthritis Foundation's (Northern California Chapter) inaugural Arthritis Expo held in Santa Clara. Swiss Medica provided sponsorship funding, substantial product sampling, and on site participation by medical professionals.

The event provided an excellent opportunity to sample Swiss Medica's flagship product O24 Pain Neutralizer to a large segment of the Foundation's membership and physicians. Due in large part to the positive reaction to O24 Pain Neutralizer, product samples will be included in Northern California Chapter Arthritis Foundation member mailing being distributed in early 2006. O24 Pain Neutralizer is a medically and clinically tested product that has made a significant difference in the lives of many people living with the day to day challenges of pain associated with arthritis.

James R. Bouquin, President of the Northern California Chapter of the Arthritis Foundation says "Swiss Medica exemplifies the kind of corporate citizen that makes a real difference to the work of our organization and our members who are living with arthritis."

The Northern California Chapter of the Arthritis Foundation represents 2 million people in the Greater San Francisco Bay area managing Arthritis.

..dürften angesichts der ständig guten Nachrichten, deutlich höher als die prognostizierten 2 Mio. USD sein! Ich rechne mit 2,3 - 2,6!

DEL LA RUE Börsenbrief: Ausgabe I-05,
2. Dezember 2005

O24 in über 21,000 Geschäften

Seit der Einführung von SwissMedica‘s O24 Pain Relief sind nicht einmal drei Jahre vergangen und das Unternehmen konnte schon jetzt bekannt geben, das O24 in über 21,000 Geschäften in den USA und Kanada käuflich zu erwerben ist. Abnehmer von O24 sind vor allem große Drugstores, wie CVS, Rite Aid, Longs Drugs, Walgreens aber auch Wal-Mart (Kanada).

Auch das neuste Produkt O24 Fibromyalgia, soll bis Jahresende in über 10,000 Geschäften zu kaufen sein.

Die Geschichte von SwissMedica, halten wir nach wie vor für äußerst interessant und lukrativ. Wir können daher unseren Lesern nur empfehlen, in diesen Wert investiert zu sein.

Erste Informationen von Swiss Medica Deutschland.

Auf der Homepage www.swissmedica.de, bietet das Unternemen erste Informationen über eine Anlage:

Zinssatz: 12 %
Laufzeit: 5 Jahre
min. Anlagebetrag: 200.000 EURO

Informationen über das Unternehmen und Produkte sollen anfang 2006 erscheinen.

Folgende neuen Zinssätze wurden uns von Ronald F. Springer bestätigt:

in den USA eine 12% Verzinsung
in der EU eine 9,5% Verzinsung

Swiss Medica Confirms Record Net Revenues in Excess of US$2 Million in Fourth Quarter
Thursday December 22, 8:00 am ET

TORONTO--(BUSINESS WIRE)--Dec. 22, 2005--Swiss Medica, Inc. (OTCBB:SWME - News) is pleased to announce that net revenues for the fourth quarter ending December 31, 2005 will be in excess of US$2 million. This revenue level is in line with the updated guidance that was given in the press release dated October 19, 2005. Fiscal 2005 revenues will be in excess of US$6.3 million.

Swiss Medica will announce final fourth quarter net revenues and other fourth quarter operating highlights by January 13th, 2006. Full fourth quarter and fiscal 2005 audited financial statements will be included in the Company's 10-K, which will be filed with the U.S. Securities and Exchange Commission by March 31, 2006.

Swiss Medica CEO Raghu Kilambi commented, "We are pleased with our continued growth in the fourth quarter and growing acceptance for our three products in North America. We are confident that 2006 will bring further growth and expansion into new channels and markets."

Update zu folgendem Artikel von AllPennyStocks.com
15.07.2003

"SWME recently announced it's first investment in Doctor's Natural Solutions Inc. in a deal that will ultimately result in Swiss Medica acquiring a biosciences product called Ayala, a significant discovery in the field of "Blood Sugar Management." Doctor's Natural Solutions, based in Clearwater, Florida, developed Ayala, a herbal product suite with potential practical applications ranging from significant weight loss and weight management to diabetes therapy. After two years of development and a number of successful case studies, Ayala is expected to be ready for commercialization in 2003."

Nach längeren Recherchen haben wir erfahren, dass der Deal aus nicht bekannten Gründen platzte und das Produkt sowie das Unternehmen "Doctor's Natural Solutions", nicht länger bestehen.

Quelle: www.dellarue.de

und heute kommen die Zahlen, die anscheind sehr positiv ausfallen.  

Swiss Medica Deutschland GmbH Update

Fast zwei Monate nach bekanntwerden der Swiss Medica Deutschland GmbH,
wurde der Internetauftritt zu heute wesentlich verbessert.

Die Swiss Medica Deutschland GmbH bietet interessierten Anlegern ausfühliche Informationen über den Erwerb von Genussscheinen.

Der Genussschein bedarf einem Mindestinvestment von derzeit noch 200.000 EURO.
Die verzinsung beträgt 9,5% pro Jahr. Nach zwei Jahren fester Laufzeit besteht die Möglichkeit das Investment jährlich zu verlängern oder zu kündigen.

Produkte und Unternehmensinformationen sollen schon in Kürze folgen.

Ihr
DEL LA RUE
Investment Team

4. PMS Escape, the only clinically proven OTC product to help ease mood and appetite symptoms of pre-menstrual syndrome is now available at CVS Pharmacy. PMS Escape was developed by renowned MIT (Massachusetts Institute of Technology) academics, and completed successful double blind studies at MIT, Harvard and University of Pennsylvania with excellent results.

5. O24 samples and product information are being distributed by thousands of physicians and other medical professionals to their patients in Canada and USA.

Swiss Medica's management will host a conference call on Wednesday January 25th, 2006 at 4:00 pm EST to discuss the Company's fourth quarter highlights and go forward strategy. Callers from the Toronto area are invited to dial 416-695-9753 at that time to participate. All other callers are invited to dial 1-877-888-4605 to participate. The conference will also be webcast with a direct link from www.swissmedica.com.

Swiss Medica CEO, Raghu Kilambi commented "We are pleased with Swiss Medica's growth in 2005 and are confident that 2006 will be a watershed year for the company and its products as we capitalize on the branding achievements of 2005, and expand distribution of our products into new geographical markets and other channels."

Full fourth quarter and fiscal 2005 audited financial statements will be included in the Company's 10-K, which will be filed with the U.S. Securities and Exchange Commission by March 31, 2006.

Swiss Medica's O24 Pain Neutralizer Is One Of Canada's Top Selling Topical Pain Relief Products

TORONTO--(BUSINESS WIRE)--Jan. 18, 2006--Swiss Medica, Inc. (OTCBB:SWME) is pleased to announce that according to sales rankings for the latest 52-week period ending November 30, 2005 by ACNielsen, the 30ml spray bottle of O24 Pain Neutralizer was ranked the fourth best selling product in the topical analgesic pain relief category in Canadian drug stores, based on dollar sales at the retail level. O24 Pain Neutralizer was nationally launched in Canadian drug stores in September 2004.

Swiss Medica's Vice President Canadian Sales, Anne Dundon commented "O24 Pain Neutralizer has continued to prove itself in the retail marketplace in Canada. The product is gaining strong acceptance from consumers suffering from muscle aches and pains - plain and simple, this patented all-natural product works."

Swiss Medica's President and COO, Grant Johnson noted "We are extremely pleased with the quick acceptance this product has gained in Canada from consumers, retailers and the medical community within 15 months of national distribution. Our Canadian business recorded just under C$2.0 million in net revenues for 2005 (approximately US$1.7 million) and we expect continued high growth in 2006 as we launch O24 Fibromyalgia and PMS Escape into the Canadian marketplace. In addition, the success of O24 Pain Neutralizer is an excellent indicator of the potential for O24 in the United States as Canada's population is approximately 10 percent the size of that of the United States."

Swiss Medica Inc. - Highflyer 2006
17.01.2006

Das Investment Team von “DEL LA RUE“ ist sich nach den guten Zahlen vom 4. Quartal einig, Swiss Medica wird ein Highflyer in 2006.

Spektakuläre Kurssprünge sind nach der Erstempfehlung im August 2005 ausgeblieben. Stattdessen verlor die Aktie bis zu 60% an Wert.

Steigt der Umsatz wie zuletzt pro Quartal um gut 20%, dürfte Swiss Medica 2006 Umsätze von über 10 Mio. USD einfahren. Das entspricht fast der derzeitigen Marktkapitalisierung. Für ein Unternehmen das seine Geschäftstätigkeiten erst 2003 aufgenommen hat und sich auf Expansionskurs befindet, wäre eine drei bis fünffache Marktkapitalisierung angemessen.

Zudem könne man bei Swiss Medica auch in naher Zukunft mit weiteren Produkteinführungen rechnen, was bei den Anlegern für große Spekulationen sorgen wird. Wir erinnern daran, das Swiss Medica 2003 neun deutsche Patente von General Cosmetics Corp. Erwarb, wobei bereits drei Marktfähig waren.

Ende 2005 wurde in Deutschland das Tochterunternehmen „Swiss Medica GmbH Deutschland“ gegründet, eine Bekanntgabe liegt noch immer nicht vor. Auf der Homepage wird aber bereits für eine Anlage geworben. Am 25. Januar wird eine Konferenz gehalten, wo Raghu Kilambi über weitere geschäftliche Maßnahmen, sowie über die Expansion in neue geographische Gebiete informieren wird. Für uns ein Hinweis, dass über die EU-Expansion, sowie die Ausgabe der Genusscheine informiert werden soll.


Für uns ist Swiss Medica Inc. ein klassisches aufsteigendes Pioneerunternehmen.

Wir stufen die Aktie mit Strong-Buy ein und erhöhen unser Kursziel.

Unser 12-Monats-Ziel beträgt 0,60 USD (Marktkap. 58 Mio. USD)
Unser 24-Monats-Ziel beträgt 1,04 USD (Marktkap. 100 Mio. USD)

Erstmals isnd noch auch Produktmuster über das Kontaktformular abrufbar.

Ebenfalls wird die Homepage momentan fast täglich aktualisiert, sprich, es sind nun auch erste Erfahrungsberichte und Kontaktadressen, sowie Bilder von den Produkten Online.

In early 2005, Swiss Medica conducted research which involved a double blind clinical trial by Dr. Gordon Ko (Head, Fibromyalgia Clinic) and Dr. David Berbrayer (Head, Dept. Rehabilitation Medicine) at Sunnybrook & Women's Health Sciences Centre (University of Toronto). This clinical trial, conducted over a four to six week period, compared O24 Fibromyalgia against a placebo in patients suffering with Fibromyalgia. For participants who used O24 Fibromyalgia, more than 90 per cent of the patients reported mild to markedly better improvement on the 7-point Lanier rating scale, versus 7 per cent who used the placebo. Nearly 54% reported moderately better or markedly better results using O24 Fibromyalgia instead of the placebo.

Swiss Medica's President and Chief Operating Officer, Grant Johnson stated "The launch of O24 Fibromyalgia in Canada represents a number of firsts. This is the first patented product specifically for people with Fibromyalgia. We are the first to enter into a strategic and mutually beneficial agreement with Canada's national voice for the Fibromyalgia community, the FM-CFS (Fibromyalgia and Chronic Fatigue Syndrome) of Canada. Last and certainly not least, O24 Fibromyalgia is the first specific Fibromyalgia product to be available nationwide over-the-counter in Canada's largest drug store chain."

As a reminder, please note that Swiss Medica will be hosting a shareholder conference call on Wednesday, January 25, 2006 at 4:00pm EST. Toronto area callers are asked to dial 416 695 9753. All other callers, please dial 1 877 888 4605.

The conference call will also be webcast with a direct link on www.swissmedica.com.

Die wichtigsten Fakten von der Konferenz:

- 024 in über 21.000 Geschäften
- 024 viert Bestverkauftes Schmerzmittel in den USA
- 024 verkauf in Mexiko für 2006 geplant
- 024 verkauf in anderen Ländern geplant
- 024 Werbekampgane "Postcards to order Examples" geplant
- 024 Fibro USA Verkaufspotential Aufgrund späterer Einführung noch hinter Kanada
- 024 Fibro Werbekampagne läuft auf Hochtouren
- 024 Firbo durch NFA ausgezeichnet
- PMS Escape verkauf in Kanada für 2006 geplant
- neue Finanzierung geplant
- keine neue Aktienausgabe und nä. Zeit geplant
- den Wechsel in einen neuen Index geplant

O24 Pain Neutralizer is 3rd Best Selling Topical Pain Reliever in Canada in 2005, Outselling Ben-Gay'TM', Tiger Balm'TM' And Icy Hot'TM'

TORONTO--(BUSINESS WIRE)--Jan. 30, 2006--Swiss Medica, Inc. (OTCBB:SWME) is pleased to announce that according to AC Nielson sales rankings for the 52-week period ending December 24, 2005, the 30ml spray bottle of O24 Pain Neutralizer was ranked the 3rd best selling product, out of 257 products, in the topical analgesic pain relief category in Canadian drugstores, based on dollar sales at the retail level. O24 Pain Neutralizer was nationally launched in Canadian drugstores in September 2004.

Swiss Medica's Chief Executive Officer, Raghu Kilambi noted "This is a very competitive market, where Canadian consumers have over 250 choices for topical pain relief products. The fact that O24 Pain Neutralizer outsold established brands such as Ben-Gay(TM), Tiger Balm(TM) and Icy Hot(TM) in dollar sales at drugstores in 2005 within 15 months of its national launch in Canada, validates O24 as a product that works for pain relief and a brand with tremendous growth potential. Swiss Medica plans to continue to build O24's market share via public relations and product sampling to both the medical community and consumers. I would like to thank the Canadian consumers who have tried O24 Pain Neutralizer and recommended it to their friends and family, in addition to the Swiss Medica team and our valued retail partners."

O24 Pain Neutralizer is now available at over 21,000 retail outlets in North America, compared to under 2,000 retail outlets at the beginning of 2005.

Ben-Gay is a registered trademark of Pfizer Corporation. Tiger Balm is a registered trademark of Haw Par Healthcare Ltd. Icy Hot is a trademark of Chattem, Inc.

Im 4. Quartal wurde “024 Fibromyalgia“ in den USA und im 1. Quartal 06 in Kanada eingeführt. Derzeit führen bereits über 10.000 Geschäfte das von der NFA ausgezeichnete Produkt, bis zum ende des 1. Quartals 06 sollen es bereits über 15.000 sein. Raghu Kilambi bekräftigt zwar, dass das Geschäft mit “024 Pain Neutralizer“ in den USA aufgrund der verspäteten Einführung noch nicht so stark wie in Kanada läuft, ist sich jedoch sicher, dass sich der amerikanische Markt ähnlich dem kanadischen Markt entwickeln werde. Man unterzeichnete daher ende 2005 ein Vertrag über groß angelegte Werbekampagnen, die bereits Ende 2005 angelaufen sind. So werden bereits Millionen von Proben über Ärzte und Kliniken verteilt. Über eine zusätzliche “Postcard Kampagne“ werden Millionen von Haushalte angeschrieben, die sich dann kostenlose Proben bestellen können. Durch diese Aktionen erhofft sich Swiss Medica einen waren “run“ auf die Produkte. In Testregionen, wo zahlreiche dieser Kampagnen bereits gestartet wurden, sprachman von Ausverkäufen in den nahe gelegenen Drugstores.

Zudem plane man für 2006 bereits die Expansion in den mexikanischen Markt.Auf andere internationale Märkte wird ebenfalls bereits ein Auge geworfen.

R. Kilambi sprach ebenfalls über die finanzielle Lage, danach hatte Swiss Medica zum Ende des 3. Quartals 05 ein Cashbestand von 700 TUSD, sowie ein Lagerbestand, der einen Umsatzerlös von 15 Mio. USD entspricht. Die Geschäftstätigkeiten sollen auch ohne neue Aktienemissionen aufrecht erhalten werden, um dies zu gewährleisten sprach Raghu Kilambi von einer neuen Finanzierung, die er jedoch noch nicht näher benennen möchte *(Wie wir bereits zuvor berichtet haben, wird auf der deutschen Swiss Medica Homepage, bereits für diese Finanzierung geworben.)


* Angaben vom DEL LA RUE Investment Team
Quelle: Live Konferenz, abrufbar unter www.swissmedica.com “Shareholders Webcast“

Khandaker Partners Issues Valuation Report On Swiss Medica
Wednesday February 1, 8:00 am ET

TORONTO--(BUSINESS WIRE)--Feb. 1, 2006--Swiss Medica, Inc. (OTCBB:SWME - News) is pleased to announce that Khandaker Partners, a New-York City based independent research and advisory firm specializing in small cap and emerging growth healthcare companies, has prepared an independent valuation report on the Company. Swiss Medica paid $15,000 cash for the report.

Copies of the full report can be obtained by emailing rripatti@khandaker.com

SWME’s flagship product, the O24 Pain Neutralizer (US Patent #6,444,238B1) is a topically applied pain reliever that has proven effective in treating chronic pain. Unlike expensive prescription drugs that has been shown to cause dangerous side effects, the O24 Pain Neutralizer uses all-natural ingredients to provide a safe and natural pain solution for minor aches and pains associated with all types of chronic pain and temporary ailments.

SWME recently launched its patented O24 Fibromyalgia pain reliever (US Patent #6,444,238B1) in North American retailers. The O24 Fibromyalgia is the first and only product specifically for fibromyalgia pain that is available in national pharmacies. Fibromyalgia is a chronic condition causing pain, stiffness and tenderness of the muscles – and it is very difficult to treat. Over 10 million Americans suffer from the long-term pain associated with fibromyalgia and the clinically tested and proven O24 Fibromyalgia targets this segment. The National Fibromyalgia Association (“NFA“) awarded O24 Fibromyalgia their first NFA Seal of Approval – a significant endorsement from the industry’s renowned association. Both the O24 Pain Neutralizer and O24 Fibromyalgia address a combined market size worth estimated over $9 billion.

SWME also manufactures PMS Escape (US Patent #'s 5760014 and 5612320). PMS Escape is the first clinically proven OTC product for the treatment of mood and appetite symptoms associated with Premenstrual Syndrome (PMS) and is made from a specially formulated group of carbohydrates, vitamins and minerals. PMS Escape targets a market size worth estimated over $2 billion worldwide and is expected to be launched nationwide in 2006.

In addition, the Company also plans to launch other OTC chronic ailment products that address other segments such as cholesterol and depression. These products are expected to be introduced in 2007 and will solidify the Company’s emerging status as a leading and comprehensive provider of elite chronic ailment treatment solutions.

Company Highlights and Investment Considerations

• Large Addressable Market Opportunities: Every year more than 65 million Americans spend over $18 billion to treat chronic pain ailments. SWME’s products address a major portion of this market and are price-positioned to fill a huge market void between much higher priced prescription products and lower priced OTC products. The growth of the U.S. herbal/natural market ($5 billion) also provides a strong fundamental backdrop for the Company sustaining long-term growth.

• Differentiated Business Model: Unlike heavy spending high-risk drug development firms, SWME spends wisely and acquires patents/licenses of clinically tested all-natural ingredient products that treat chronic aliments and that also address sizeable market opportunities. SWME’s products provide effective solutions to treat chronic ailments without the negative side effects of prescription products and compares favorably in effectiveness and price against both OTC and prescription products. SWME’s strong management team has a proven record in building companies, marketing and business development.

• Unique Patented OTC Products Yield High Gross Margins: SWME has launched the first product for fibromyalgia available in national pharmacies and has also launched the only clinically proven OTC product for PMS. SWME’s patented exclusive products with strong intellectual property have yielded gross margins similar to prescription drug levels at 75-80%.

• Solid Clinical/Medical Tests: All of the SWME’s products have been clinically tested in various medical studies and shown to be efficacious in treating chronic pain ailments. The O24 Fibromyalgia is the only product in the market that has been clinically tested and proven effective in treating fibromyalgia symptoms which afflicts about 10 million Americans. Other drug development firms have failed in recent endeavors and competing products appear to be years away from hitting the market.

• Strong Revenue and Op. Income Growth: In 2006, we are projecting revenues of $16.79 million (+162% vs 2005E) and operating income of $1.24 million, compared to 2005 estimated revenues of $6.42 million and net operating loss of $4.71 million. We believe the Company is primed for stellar revenue growth over the next five years and project 5-yr revenue CAGR of 68% with revenues conservatively reaching $86.9 million by 2010. Operating and net income should follow similar growth rates since Company’s gross margins exceed 70% annually.

First Randomized Double Blind Clinical Trial on Swiss Medica's O24 Fibromyalgia Published in Medical Journal
Business Wire - February 02, 2006 08:00

TORONTO, Feb 02, 2006 (BUSINESS WIRE) -- Swiss Medica, Inc. (OTCBB:SWME) is pleased to announce that the randomized double blind clinical trial using O24 Fibromyalgia on patients suffering from Fibromyalgia has been published in the Practical Pain Management Journal, January/February 2006 issue (www.ppmjournal.com). This publication reaches over 37,000 medical professionals in the United States, including physicians, Occupational Health Professionals and Pain Specialists.

The clinical trials were conducted by Dr. Gordon Ko, Medical Director of the Canadian Centre for Integrative Medicine and were run from October 2004 thru January 2005. The results of the clinical study were analyzed by the Institute of Clinical Evaluative Studies, (ICES) in Toronto.

"This publication represents the first time a clinical study for O24 has been published in a medical journal," said Grant Johnson, President and COO of Swiss Medica. "The findings of the clinical study indicate that the topical O24 product was superior to placebo in the management of Fibromyalgia Syndrome (FMS), with significant improvements documented in both subjective surveys of pain/dysfunction and in objective measures of algometry and hand dynamometry."

Dr. Gordon Ko (Head, Fibromyalgia clinic) and Dr. David Berbrayer (Head, Dept. Rehabilitation Medicine) at Sunnybrook & Women's Health Sciences Centre (University of Toronto), directed this 4-6 week pilot study of 153 Fibromyalgia subjects. Of these, 133 participants (87%) completed the study with 68 (51%) using a placebo. The other 65 (49%) used the O24 product. Assessments of these participants were carried out at multiple community clinics in the Greater Toronto Area.

"The group treated with O24 compared to placebo showed statistically significant improvement when measured on the Visual Analog Scale for pain," noted Dr. Gordon Ko, who is also the Medical Director for the Canadian Centre for Integrative Medicine in Markham, Ontario. Dr. Ko's clinical study was statistically peer-reviewed by Marko Katic, biostatistician at the Institute of Clinical Evaluative Studies (ICES).

Improvement was also statistically significant for VAS night pain, Jamar hand-grip strength, total number of Fibromyalgia tender points and the average tender point pain threshold as measured by algometry.

- For participants who used O24, 88% of the patients reported mild to markedly better improvement on the 7-point Lanier rating scale. 53% reported moderately better to markedly better improvement using O24.

- Only 7% reported mild improvement from the placebo on the 7-point Lanier rating scale. 79% of the placebo group reported no change in their condition and 14% reported a worsening of their condition.

Dr. Ko concluded about O24, "With the demise of traditional medications, such as the Cox-2 inhibitors, the use of therapies that have such clinical effectiveness, and minimal to insignificant side effects, is exciting news."  

und die Ralley dürfte weiter gehen.
mehr News werden in kürze folgen.
Darf leider aus Insider Gründen keine nennen,
nur soweit, das es ordentlich cash in der Kasse geben wird! (Eigenkapital)

Swiss Medica Inc. launches Distribution of Products into U.S. Healthcare Industry

Swiss Medica, Inc. (SWME) announced a U.S. healthcare industry distribution deal with North American Physicians, Inc., ("NAPI" of Boca Raton, Florida. NAPI will distribute all three of Swiss Medica's products (O24 Pain Neutralizer, O24 Fibromyalgia and PMS Escape) into the healthcare community including licensed dispensing physician offices, physician kiosks, pain management clinics, hospitals, therapy centers, hospital pharmacies, and chiropractor and podiatry clinics. The sampling and sale of products will be by healthcare professionals to patients in medical settings, experiencing either acute or chronic pain afflictions as well as mood instability.

Swiss Medica to Participate at the Upcoming U.S. Pain Management and Rheumatology Conferences
Thursday February 9, 8:00 am ET

TORONTO--(BUSINESS WIRE)--Feb. 9, 2006--Swiss Medica, Inc. (OTCBB:SWME - News) is pleased to announce that on February 11, 2006, Chief Executive Officer, Raghu Kilambi and Lynne Matallana, President and founder of the National Fibromyalgia Association, of Orange, California are invited guest speakers at the upcoming American Osteopathic College of Rheumatology's Continuing Medical Education conference in Reno, Nevada. Mr. Kilambi and Ms. Matallana will be lecturing on pain relief and fibromyalgia, respectively and how O24 Pain Neutralizer and O24 Fibromyalgia are safe and effective pain relief treatments for chronic pain and fibromyalgia.

In addition, from February 23 -25, 2006, Swiss Medica will be exhibiting and sampling medical professionals at the American Academy of Pain Medicine 22nd Annual Meeting in San Diego, CA. It is expected that over 800 pain management specialists from across the United States will be attending this 3-day conference.

Please note, Dr. Robert S. Maurer was incorrectly identified in our press release dated February 6, 2006, as a past president of the American Osteopathic Association. He has never served in that position, although he is an active member of that organization. He is currently serving as the Executive Director of the American Osteopathic College of Rheumatology and has served on their Board of Directors for many years.

Die Alpha Capital Aktiengesellschaft hält nach dem am 08.02.2006 veröffentlichtem SEC Filing jetzt 4.552.000 Aktien von der Swiss Medica Inc.

Das zeigt doch das große Interesse seitens institutioneller Anleger!

Erste öffentliche Werbung für den Genusschein von Swiss Medica auf www.classiccars-bavaria.de

Swiss Medica Appoints Trained Physician and Experienced Businessman Sam Halim to Board of Directors

TORONTO--(BUSINESS WIRE)--Feb. 23, 2006--Swiss Medica, Inc. (OTCBB:SWME) is pleased to announce the appointment of Sam Halim to the Board of Directors.

Sam Halim is a trained physician and has over 15 years of business experience in the healthcare, financial services and real estate industries. Mr. Halim founded, acquired and managed multiple medical service facilities in Florida that cared for over 70,000 patients and serviced over 2,000 physicians. Mr. Halim sold the medical facilities in 2002. Mr. Halim has successfully recruited, managed and employed many physicians and healthcare professionals during his career. Mr. Halim recently launched North American Physicians Inc. (NAPI) to distribute Swiss Medica's elite OTC products to the healthcare industry. Mr. Halim studied at University of Cairo Medical School (in association with University of London), New Jersey School of Osteopathic Medicine and Columbia University.

Swiss Medica's Chief Executive Officer, Raghu Kilambi noted, "Sam Halim has already made a significant impact on Swiss Medica in terms of distribution opportunities in the healthcare industry. In addition, his international business relationships are invaluable to Swiss Medica as we start to evaluate international markets outside of the United States and Canada. Mr. Halim's physician training and diverse business background is a valuable addition to our Board of Directors."

Mr. Halim commented, "The overwhelming embracing of Swiss Medica's products by the healthcare professionals and the positive results from their patients has been amazing. I am looking forward to working with Swiss Medica to achieve widespread distribution of Swiss Medica's elite OTC products in the healthcare industry."

Swiss Medica Samples O24 Pain Neutralizer To One Million Seniors In USA

TORONTO--(BUSINESS WIRE)--Feb. 28, 2006--Swiss Medica, Inc. (OTCBB:SWME) is pleased to announce the launch of the first wave of its largest consumer sampling program to date, reaching 1 million seniors in late February/early March with information and a sample of O24 Pain Neutralizer. The first sampling program took part in senior publications in Boston, Chicago, Los Angeles, New York, Phoenix, and various markets in Florida.

"When we sampled seniors directly in the past, sales at retail in those markets increased dramatically over markets where we did not do direct sampling", said Wendy Kramer, Vice President of Swiss Medica. "We are very excited about this large national sampling program and plan on reaching millions of consumers and allied health professionals with product samples and information in 2006."

The towelette sample was attached to an informational postcard and inserted into senior newspapers that were either mailed to the consumer or available in their apartment or senior center.

O24 Pain Neutralizer is available nationally in retailers in North America, including CVS/Pharmacy, Walgreens, Rite Aid and Shoppers Drug Mart.

Quelle: DEL LA RUE Forum

"This is a real life issue, and it makes total sense to incorporate it into the real life conversations we have every day at ChickChat," added co-host Heidi Hanzel.

The PMS-ChickChat partnership was launched several weeks ago, and has already had a positive impact on awareness of PMS Escape and consumer demand.

About ChickChat Radio:

ChickChat Radio is a nationally syndicated, female-hosted talk radio show for the 25-54 demographic. ChickChat is a contemporary, relevant, stylish, unique, non-political, entertaining, not for-women-only radio show hosted by Heidi and Lara -- two women with no loss for words or opinions. Recently honored as 'Rising Stars of Talk Radio' by Radio and Records Magazine, co-hosts Heidi and Lara have also been featured guests on the national Fox News Channel. Their show is broadcast live each weekday with studios in New York City and Washington D.C. ChickChat can be heard on stations nationwide, Sirius Satellite Radio, worldwide via www.chickchatradio.com and daily podcasts.

hat nun die Chancenund Risiken veröffentlicht.
Ich nehme an es geht jetzt in die heisse Phase, wenn das Prospekt geprüft und veröffentlicht wurde, sollte die Zeichnung beginnen, und SWME Inc. schnell an bares gelangen. In diesem Zusammenhang dürfte sich der Kurs mit der Unterstützung bie 0.15 USD schnel auf die Wege Richtung Widerstandlinie bei ca. 0.22 USD bewegen.  

Swiss Medica Announces That O24 Fibromyalgia is Now Available at CVS/Pharmacy

TORONTO--(BUSINESS WIRE)--March 14, 2006--Swiss Medica, Inc. (OTCBB:SWME) is pleased to announce CVS/Pharmacy is now selling O24 Fibromyalgia nationwide in the pain relief section of their pharmacies.

"We are very excited that CVS/Pharmacy has added O24 Fibromyalgia to their topical pain set, said Wendy Kramer, Vice President of Swiss Medica. We believe that this will offer millions of fibromyalgia patients a convenient opportunity to purchase O24 Fibromyalgia for their pain."

Swiss Medica is Title Sponsor of the National Fibromyalgia Association-Fibromyalgia Patient and Medical Education Conferences

TORONTO--(BUSINESS WIRE)--March 15, 2006--Swiss Medica, Inc. (OTCBB:SWME) is pleased to announce that it is the title sponsor of the National Fibromyalgia Association (NFA) - Fibromyalgia Patient and Medical Education Conference (FAME) (March 16-19) in Anaheim, California. FAME will bring together patients, physicians and medical researchers, and is expected to be the most comprehensive patient and medical education/research conference ever held to help people suffering with the chronic symptoms of fibromyalgia.

Swiss Medica in conjunction with the NFA is co-sponsoring the 2nd Annual "Leaders Against Pain" Advocacy and Media Training seminar. The two-day seminar will teach the participants how to work with the media and develop local advocacy programs to support efforts on behalf of people with fibromyalgia and other chronic pain illnesses. The seminar will also have a Q&A session with prominent journalists

"We are proud to participate in this milestone event with the NFA," said Grant Johnson, President and COO of Swiss Medica, manufacturers of the new O24 Fibromyalgia topical pain reliever. "This training seminar has all of the top influencers in the fibromyalgia community gathered in one location, this is the most important event we could attend to raise the awareness of O24 Fibromyalgia in the medical and patient communities."

O24 Fibromyalgia is a patented and clinically tested over-the-counter topical pain reliever for fibromyalgia. O24 Fibromyalgia is the first OTC or prescription product specifically for fibromyalgia that is available in national retailers was recently awarded the first NFA Seal of Approval. O24 Fibromyalgia is available nationally in the United States and Canada in leading pharmacies.

für die Genussscheine der Swiss Medica Beteiligungs GmbH wird jetzt auf der Seite vom DEL LA RUE - Investment Team geworben.

www.dellarue.de

Im DEL LA RUE - Forum findet man ebenfalls ein großen Rückblick was Nachrichten und Empfehlungen angeht.

Ein wesentlicher Faktor liegt dabei in der Unterstützung durch die Swiss Medica Beteiligungs- GmBH. Diese wird in den nächsten Monaten die Neufinanzierung einleiten und dadurch die Pläne und Ziele der Swiss Medica Inc. erst ermöglichen. Die ersten Vorbereitungen wurden bereits getroffen und man kann schon heute Genussrechte bei der Swiss Medica beteiligungs– GmbH zeichnen. Interessierte Anleger können sich direkt an “info@swissmedica.de“ mit dem Betreff: “Genussschein via DEL LA RUE“ wenden.

Aus heutiger Sicht ist das Unternehmen hervorragend aufgestellt und wird sich in Zukunft global behaupten können. Wir halten die Zeichnung von Genussrechten oder den Kauf von Aktien, als Chance an einer grandiosen Erfolgsgeschichte teilzuhaben und zu profitieren.

Wenn Sie den komplette Bericht: Swiss Medica Inc. ...unser “BULLE 2006“, erhalten möchten, senden Sie uns bitte eine E-Mail, mit dem Betreff:“Bulle 2006“, wir senden Ihnen dann umgehend die 350 KB große PDF-Datei. Mehr Informationen auch unter www.dellarue.de

Rating: A++
Anlagehorizont: bis 4 Jahre

Autor: Investment – Team Dellarue (www.dellarue.de)

Copyright 2006 traders inc./ Del La Rue

Der Bericht hört sich echt vielversprechend an.

@ Lancer... aber erstmla herzlich willkommen, dass ist ja schließlich der erste Fremdeintrag hier in, man könnte fast sagen "meinem", Forum. Denn bisher gab es nur Leser, mitreden wollte noch keiner!

Besser investieren...

Rendsburg, 29.03.2006
Was ist Ihnen wichtig?... Gesundheit und Wohlstand? Dann gilt es diese Wünsche zu kombinieren und sprichwörtlich „ Zwei Fliegen mit einer Klappe zu schlagen“. Wir sehen diese Chance nach wie vor mit einer Anlage in die Swiss Medica Inc.!

ISIN: US87089C1045
Symbol: SWME.OB
www.swissmedica.com
Www.swissmedica.de

Mit innovativen Produkten und Blockbustern können Anleger wahrlich viel Geld verdienen. Es gilt jedoch ein Unternehmen zu finden, in dessen Produkten man dieses Potential vermuten kann. Mit swissmedica haben wir ein Unternehmen gefunden, welches mit “024 Pain Neutralizer“, “024 Fibromyalgia“ und “PMS Escape“, drei innovative Produkte vertreibt, in denen wir Blockbusterpotential vermuten. Die Produkte basieren auf einer homöopathischen Grundlage und sind klar im Vorteile gegenüber ihren pharmazeutischen Konkurrenten. Sie haben nachweislich keine Nebenwirkungen, wirken schneller, sind preiswert und nicht rezeptpflichtig. Die Produkte von swissmedica haben das Potential, pharmazeutische Produkte vom Markt zu drängen und sind dabei ein fester Bestandteil der Gesundheitsindustrie zu werden. Ein erster Durchbruch ist bereits gelungen, als erstes Produkt wurde “024 Fibromyalgia“ durch seine nachweislich gute Wirkung, von der NFA (National Fibromyalgia Association) mit dem “NFA Seal“ ausgezeichnet. Die NFA rät ihren Mitgliedern sogar zum Kauf von “024 Fibromyalgia“.


Der swissmedica Rückblick...

Nicht einmal drei Jahre benötigte “024 Pain Neutralizer“, um in Kanada das drittbestverkaufte Produkt seiner Klasse (gemessen am Dollar Umsatz), von über 250 vergleichbaren Produkten, zu werden. Diese sagenhafte Performance macht deutlich, welches Potential in der “024 Serie“ steckt. In den USA steht diese Potential erst in den Startlöchern. Durch die spätere Einführung in den amerikanischen Markt und die erst vor kurzem gestartete Werbekampagne, kann swissmedica erst in diesem Jahr von einem wahren Durchbruch auf dem amerikanischen Markt hoffen.

Die ambitionierte Prognose von Umsätzen zwischen 12 und 14 mio. USD für das letzte Geschäftsjahr, sind demnach nicht völlig verfehlt. Das Management war am Anfang 2005 sehr euphorisch über die enormen Umsatzzuwächse und der positiven Resonanz von den Konsumenten, Kunden und Ärzten. Dabei wurde angenommen, dass die Quartalsumsätze weiter im dreistelligen Prozentbereich zunehmen würden. Zeitliche Verzögerungen bei der Einführung von “024 Fibromyalgia“ und “PMS Escape“ machte den Unternehmensprognosen einen Strich durch die Rechnung. Zudem war es nicht möglich, die Umsatzzuwächse auf einem so hohen Level beizubehalten. Über das letzte Jahr konnte das Unternehmen jedoch konstante Quartalszuwächse zwischen 20 bis 30% ausweisen. Prognosen für das kommende Jahr liegen noch nicht vor. Durch die aggressive Marketings- und Expansionspolitik ist anzunehmen, dass die Zuwächse in 2006 auch innerhalb dieser Marge liegen werden, in günstigen Marktsituationen sogar überschreiten werden. Eigenen Kalkulationen zufolge, gehen wir in 2006 von Umsätze zwischen 12 bis 16 Mio. USD aus. Im Vergleich zum Vorjahr sollte der Zuwachs deutlich im dreistelligen Prozentbereich liegen. Eine genaue Prognose ist jedoch äußerst schwierig, da das junge Unternehmen erst am Anfang seiner Blütezeit steht.


Produkte finden reißenden Absatz

Die Produkte von swissmedica sind mittlerweile in über 29.000 amerikanischen und kanadischen Geschäfte erhältlich. Zu den Kunden gehören vor allem Großkunden, wie: Walgreens, Rite Aid, CVS, Osco Drug, Zellers, Wal-Mart (Canada), Arrow, Shopper Drug Mart, Happy Harriy‘s, uvm.

Die Swiss Medica Inc. verfügt über ein landesweites und vor allem dichtes Vertriebsnetzt. Die zahlreichen Werbekampagnen können sich nun als besonders effektiv erweisen, da Kunden die Produkte jetzt in ihrem Drugstore um die Ecke finden. Letztes Jahr wurde die Kritik laut, dass eben wegen fehlender Werbekampagnen die Umsätze nicht wie erwartet gestiegen sind. Die Kritiker berücksichtigten aber nicht, dass swissmedica zuerst ein neues Vertriebsnetzt aufbauen musste, um die Produkte in die Regale zu bekommen. Anders als ältere Unternehmen, musste swissmedica neue Geschäftsbeziehungen erst knüpfen und dafür sorgen, dass die Produkte auch Vorort zu erwerben sind. Erst dann würden sich intensive Werbekampagnen bezahlt machen. Produkte finden reißenden Absatz. Neben Großkunden will das Unternehmen in Zukunft auch andere Vertriebskanäle
aufbauen Ende Februar diesen Jahres wurde der erfahrene Arzt Sam Halim als Direktor mit ins Management aufgenommen. Sam Halim gründete die “North American Physicians Inc.“ (NAPI), um die Produkte von swissmedica über medizinische Einrichtungen direkt zu vertreiben. Der Vertieb von “024“ und “PMS Escape“ über Ärzte und Klinken bringt neben mehr Kundenvertrauen in die Produkte und höhere Absatzmöglichkeiten, auch eine größere Unabhängigkeit gegenüber den Großkunden. Der Wegfall von einem oder mehrerer Großkunden, kann somit besser aufgefangen werden. Zusätzlich erhofft man sich durch die Beratung und Betreuung der medizinischen Einrichtungen, Vertrauen und Zusprechung seitens der Ärzteschaft Dadurch könnte es der “024 Serie“ noch schneller gelingen, herkömmliche Pharmazeutiker zu verdrängen und ein festen Bestandteil der Schmerztherapieszene
zu werden.


Swiss Medica im Aufwind

Schon bald könnten die Produkte von swissmedica auch hierzulande in den Regalen stehen. Ende Januar verkündete swissmedica‘s CEO, Raghu Kilambi, dass man noch diese Jahr in Mexiko und anderen Regionen Fuß fassen möchte. Auf dem Sachs North American Biotech Forum, Anfang März, wurde dann bekannt, dass eine Expansion nach Europa kurz bevor steht. Ein erster großer Schritt, war die Ende 2005 gegründete “Swiss Medica Beteiligungs- GmbH“ mit Sitz in Bad Kötzting, ein Tochterunternehmen der “Flora Verda Medical Center & Spa GmbH“.

Unter der Führung von Ronald Springer, dem Initiator und Hauptverantwortlichem
für die erfolgreiche Entwicklung der “024 Serie“, beschäftigt sich die Swiss Medica Beteiligungs- GmbH derzeit mit der Beschaffung von frischem Kapital für die Swiss Medica Inc.. Eine Beteiligung an der Swiss Medica Inc., soll die Expansion vorantreiben, sowie die Marktposition der Swiss Medica Inc., langfristig und global sichern. In wieweit der Vertrieb hierzulande bereits geplant ist, oder sich schon in Gang befindet, ist derzeit noch nicht bekannt. Doch bereits unter der General Cosmetics Corp. wurden Teile der “024 Serie“ unter “024 Sport“ hierzulande erfolgreich verkauft. Bei eine erneute Markteinführung in Europa, gehen wir auch in Zukunft von sehr guten Absätzen aus.


In die Genüsse kommen

Beflügelt unter dem enormen Potential von der Swiss Medica Inc., sowie der bevorstehenden Expansionspolitik und den damit verbundenen Marktchancen, bremst derzeit nur die finanzielle Situation die Euphorie vieler Anleger. swissmedica kann zwar einen großen Inventarbestand ausweisen, auch Raghu Kilambi sprach im Januar von einem Warenvorrat der einen ungefähren Umsatzvolumen von bis zu 15 mio. USD entspricht. Es bestanden damals aber auch offene Forderrungen von bis zu 5 Mio. USD. Die relativ hohe Aktienanzahl von über 90 Mio. ausgegeben Aktien erschwert Swiss Medica die Mittelbeschaffung per Kapitalerhöhung. Daher hat sich die Swiss Medica Beiteiligungs– GmbH dieser Herausforderung gewidmet und neue Wege eingeschlagen. Derzeit wird mit Hochdruck an der neuen Finanzierung gearbeitet. Im Vordergrund steht dabei die Emission von Genussscheinen mit einer festen Verzinsung von 9,5% auf 5 Jahre Laufzeit. Die Genussrechte der Swiss Medica Beteiligungs– GmbH werden mit Aktien der Swiss Medica Inc. abgesichert und bieten dem Anleger daher eine hervorragende Chance sich von Anfang an am
Wachstum der Swiss Medica Inc. zu beteiligen. Schon der Mittelständler Vogeley hat erfolgreich Genussscheine emittiert und damit bewiesen, dass diese Form der Kapitalbeschaffung für kleinere Firmen eine interessante Alternative zum Bankkredit darstellt. Die Emission von Genussscheinen ist zwar schon mit den Einmalkosten von ca. 2 % bis 3% des Emissionsvolumen relativ teuer, ermöglicht neben der Verbesserung der Eigenkapitalquote aber auch eine Unabhängigkeit gegenüber Banken.

Für Anleger sind Genussscheine äußerst lukrativ. Einerseits bieten sie hohe jährliche Ausschüttungen und anderseits muss der Anleger kein Kursrisiko tragen.

Derzeit bietet die Swiss Medica Beteiligungs– GmbH nur Investments ab 200.000 EURO an, weil eine kleinere Stückelung erheblichen bürokratischen Aufwand erzeugen würde. In naher Zukunft dürfte aber auch eine kleinere Stückelung möglich sein. Interessenten für Investments unter und über 200.000 EURO, können sich direkt an “info@swissmedica.de“ mit dem Betreff: “Genussschein via DEL LA RUE“ wenden.

Quelle: www.dellarue.de  Börsenbrief Ausgabe III - 06

Nur noch ein paar Tage bis zu den Quartalszahlen, und ein erster guter Indikator lässt gutes Erahnen. 024 ist bei Walgreens Ausverkauft!

www.walgreens.com/store/...tion=jump&navCount=0&id=prod1670123

 Swiss Medica Announces That Brooks/Eckerd Pharmacy Is Now Carrying Swiss Medica's O24'TM' Products

TORONTO, ONTARIO -- (MARKET WIRE) -- 04/17/06 -- Swiss Medica, Inc. (OTC BB: SWME) is pleased to announce today that all of the Brooks/Eckerd Pharmacy stores are now carrying Swiss Medica's O24 Pain Neutralizer and O24 Fibromyalgia.

Brooks/Eckerd Pharmacy has approximately 1,855 stores throughout the United States under the Brooks Pharmacy and Eckerd Pharmacy names.

"We are delighted to be selling our products through these popular and well-established pharmacy retailers," said Swiss Medica Vice President Wendy Kramer.  

SWISS MEDICA INC: 8-K, Sub-Doc 1, 20.04.2005

On April 13, 2006 (the "First Closing Date"), the Registrant closed a
financing transaction in which it sold secured convertible redeemable debentures
(the "Convertible Redeemable Debentures") to Montgomery Equity Partners, Ltd.
("Montgomery") to raise $2,000,000 pursuant to a Securities Purchase Agreement
dated April 11, 2006 (the "Securities Purchase Agreement"). The Registrant
received $1,300,000 on the First Closing Date, and will receive the balance of
$700,000 on the date the registration statement is filed (the "Second Closing
Date") pursuant to Investors Registration Rights Agreement dated April 11, 2006
between the Registrant and Montgomery (the "Registration Rights Agreement").

• We acquired the exclusive licensing rights to PMS Escape® the first and only clinically tested and patented over-the- counter dietary supplement for the management of mood, appetite and the ability to concentrate associated with pre- menstrual syndrome, a market that effects up to 27 million women in the Unites States alone. PMS Escape® is now available in retailers in the USA and Canada.

• O24™ Pain Neutralizer has received strong endorsements from recognized leaders in sports (Olympic and professional athletes), medical professionals, and consumer associations (regional arthritis groups in North America, National Fibromyalgia Association).

• O24™ Pain Neutralizer was the third best selling Topical Pain Reliever in Canada in 2005, outselling Ben-Gay, Tiger Balm and Icy Hot (based on dollar sales), according to market research firm ACNielsen Canada.

• Swiss Medica and O24™ Pain Neutralizer were awarded Company of the Year and Product of the Year by the Northern California Arthritis Foundation in 2005.

• In a randomized double blind clinical study conducted in 2005, 88 per cent of the patients who used O24 Fibromyalgia™ reported mild to markedly better improvement from their fibromyalgia pain, versus only 7 per cent who used the placebo. The results of this study were published in Practical Pain Management, a medical journal, in January 2006.

• In addition on February 2, 2006, we announced that the Practical Pain Management Journal, in their January/February 2006 issue, published Dr. Ko’s Randomized Double Blind Clinical Trial on Swiss Medica’s O24 Fibromyalgia™.

Over the next 24-months Swiss Medica has severalmajor goals, including:

• Expand our retail distribution from our current focus on drug store chains to mass market, food and convenience retailers.

• Achieve national distribution of our products in professional channels such as physician offices, pain management clinics, chiropractors and hospital pharmacies.

• Launch Swiss Medica products into international markets outside of the United States and Canada.

• Launch other world class patented, clinically tested safe and effective products for chronic ailments such as depression and cholesterol.

• Build Swiss Medica into a leading consumer healthcare brand focused on elite over-the-counter health products for chronic ailments.

• Create substantial shareholder value.

• Move to a major stock exchange.

Swiss Medica has come a long way since its launch in mid 2003. The coming year is one of great promise and tremendous opportunity. I urge you to visit our websites www.swissmedica.com, www.O24zone.com and
www.pmsescape.com to learn more about our company and products. I am confident that you will join the thousands of people who have used our products to enhance the quality of their lives.

Thank you for your continued support of Swiss Medica.

Raghu Kilambi, CA
CEO
Swiss Medica, Inc.

Swiss Medica Launches PMS Escape Television Campaign

TORONTO, ONTARIO -- (MARKET WIRE) -- 05/16/06 -- Swiss Medica, Inc. (OTCBB: SWME) to announce that it is launching a television campaign for its PMS Escape product in the Midwest USA beginning this week. The 30-second television spot will air in Columbus, Ohio, Indianapolis, Indiana and Detroit Michigan from May 16 until June 10, 2006 and will highlight PMS Escape as a unique over-the-counter, patented, clinically tested and all-natural product for the mood and appetite symptoms of premenstrual syndrome.

Swiss Medica engaged Spot Runner, a new Internet-based advertising agency located in Los Angeles, Calif., to create the television spot and manage the campaign. Spot Runner specializes in making it fast, easy and affordable for businesses to advertise on TV. The PMS Escape 30 second TV may be viewed at www.pmsescape.net/presscenter.html.

The commercial is intended to reach women between the ages of 25 and 45 suffering from the emotional and appetite problems of premenstrual syndrome. "We took a soft approach to reaching our target audience with our first-ever television spot," explains Wendy Kramer, Vice President of Swiss Medica. "We wanted to let women know that we understand how delicate this subject matter is and how important it is to see women like themselves who can conquer the age-old problems of PMS in a natural and healthy way," Kramer continues. "We look forward to great success with our new campaign."

The spot, which highlights how PMS Escape can help women get relief from the anger, irritability and tension of PMS, will be aired during The Today Show, Good Morning America, Ellen and Oprah in the Columbus market, while Indianapolis and Detroit will air the spot on stations such as HGTV, TNT and TBS. "By airing our spots during daytime television shows, we can reach women at a time when they will really listen to what we have to say about PMS Escape," Kramer continues.

PMS Escape is available in the Feminine Hygiene section of CVS/Pharmacy and Meijers and online at Walgreens.com.  

- O24 Fibromyalgia was able to capitalize on its receipt of the first and only Seal of Approval from the National Fibromyalgia Association, based in Orange, California, to gain distribution in major pharmacies in Canada and the United States including Rite-Aid, CVS/pharmacy and Shoppers Drug Mart. O24 Fibromyalgia is the first clinically tested, patented product available in national pharmacies that specifically targets the pain associated with Fibromyalgia. There are over 11 million North Americans who suffer from Fibromyalgia.

- The results of a randomized double blind clinical study on O24 Fibromyalgia for patients suffering from Fibromyalgia was published in the Practical Pain Management Journal, (January/February 2006 issue). This publication reaches over 37,000 medical professionals in the United States. 88 per cent of the patients who used O24 Fibromyalgia in the clinical study reported mild to markedly better improvement, versus only 7 per cent who used the placebo. A copy of the published study can be viewed at www.024zone.com/Clinicals.html.

- Swiss Medica announced a U.S. healthcare industry distribution deal with North American Physicians, Inc., ("NAPI") of Boca Raton, Florida. NAPI is distributing all three of Swiss Medica's products into the healthcare community including licensed dispensing physician offices, physician kiosks, pain management clinics, hospitals, therapy centers, hospital pharmacies, and chiropractor and podiatry clinics. The sampling and sale of products will be by healthcare professionals to patients in medical settings, experiencing either acute or chronic pain afflictions as well as mood instability.

OTHER MARKETING ACTIVITIES

- Swiss Medica attended several major, medical and biotech conferences in the United States and Canada as it continued to gain exposure and acceptance from the medical community for its unique patented, clinically tested OTC products. Swiss Medica continued to gain acceptance for its products as thousands of physicians in North America requested samples of Swiss Medica products for distribution to their patients.

- Swiss Medica continued its innovative consumer brand building program of aggressive consumer sampling, public relations and targeted media to build brand recognition of all three of its products in the United States and Canada.

Summary of Financial Results: (US$000)

                              Q1/2006     Q4/2005      Q1/2005
                              -------     -------      -------
Revenues                         1,222       2,145        1,127
EBITDA                          (1,063)       (708)        (620)
Net Loss                        (1,462)     (1,254)      (1,027)
Cash Used in Operations           (399)       (796)      (2,784)


"We continue to be very optimistic about 2006 and beyond and expect significant growth as all three of our products gain momentum in the marketplace", continued Raghu Kilambi.

Swiss Medica defines EBITDA as earnings before interest and financing fees, taxes, depreciation, amortization, and other non-cash charges. Full second quarter results, for the period ending March 31, 2006, are included in the Company's 10-Q, which has been filed with the U.S. Securities and Exchange Commission.

Swiss Medica's management will host a conference call on Monday June 5th, 2006 at 4:00 pm EST to discuss the Company's first quarter highlights and go forward strategy. The details for dial-in and webcast will be forthcoming in a separate press release.

About Swiss Medica, Inc.

Swiss Medica is a specialty pharmaceutical company focused on commercializing over-the-counter clinically-tested, patented all-natural products that relieve chronic ailments. Swiss Medica builds its brands through innovative and focused distribution and marketing strategies. Swiss Medica's mission is to be a world leader in the commercialization of over-the-counter, safe and effective chronic ailment treatments. Please visit our websites at www.swissmedica.com, www.O24zone.com and www.pmsescape.com.

Swiss Medica's flagship product, the O24 Essential Oil Pain Neutralizer, holds US Patent #6,444,238B1. The O24 pain relief solution has been used and recommended for its fast-acting and long-lasting benefits by healthcare professionals and athletes in the United States, Canada and in Europe. O24 is widely available over-the-counter throughout the United States and Canada in leading pharmacies and other retailers. Customers can also visit www.O24zone.com, for ordering details and store locators for the nearest pharmacy.

Swiss Medica has recently launching the patented O24 Fibromyalgia pain reliever (US Patent #6,444,238B1) over-the-counter in North American retailers. The National Fibromyalgia Association (NFA) recently awarded O24 Fibromyalgia their first NFA Seal of Approval. Over 10 million Americans suffer from the long-term pain associated with Fibromyalgia. In a randomized double blind clinical trial conducted in 2005, 88 per cent of the patients who used O24 Fibromyalgia reported mild to markedly better improvement, versus only 7 per cent who used the placebo. Customers can also visit www.O24zone.com, for ordering details and store locators for the nearest retailer.

Swiss Medica also distributes PMS Escape® which holds US Patent #'s 5760014 and 5612320. PMS Escape® is a specially formulated group of carbohydrates, vitamins and minerals, clinically proven to reduce changes in mood and appetite that women experience during the premenstrual period. Customers can also visit: www.pmsescape.com for additional information and ordering details.

Forward-looking statements in this news release are made pursuant to the "Safe Harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including, without limitation, risks relating to acceptance of Swiss Medica's products in Canada, the United States and other countries, risks related to international sales and purchases and potential foreign currency exchange fluctuations, acceptance of Swiss Medica's products, increased levels of competition, dependence on intellectual property rights and other risks detailed from time to time in Swiss Medica's periodic reports filed with the United States Securities and Exchange Commission and other regulatory authorities.

Swiss Medica Annouces That TVA Productions Media Campaign to Support O24 Fibromyalgia Has Commenced
Wednesday May 24, 8:00 am ET

TORONTO, ONTARIO--(MARKET WIRE)--May 24, 2006 -- Swiss Medica, Inc. (OTC BB:SWME.OB - News) today announced that TVA Productions of Studio City, California has started its major media campaign supporting Swiss Medica's O24 Fibromyalgia(TM) brand building across the United States. The "MediaBlitz" campaign to be conducted by TVA Productions is based on guaranteed to result in 41,000,000 estimated gross viewer impressions and will include:

- A 60-second commercial which will has begun airing on the DISH Network. The commercials will be running from May 11 to June 13, 2006. The DISH Network delivers programming to over 12 Million households, reaching 40 million viewers.

- In June 2006, TVA Productions will release a 60-second Radio News release professionally recorded and distributed in script form and on CD to 6,600 radio stations for use on regular news and talk shows, and a 60 second VFR (Video Feature Release) which will be distributed once a month on a 23-minute "Consumer Science News & Notes" Program (CSNN) to 1,000 TV stations, nationwide.

- In June 2006, A 2 minute segment will be featured on the national 1/2 hour TV newsmagazine, "Health & Home Report" for the month of June. HHR airs on 68 broadcast stations and more than 200 cable systems, reaching into 119 different markets. A copy of the 2 minute Swiss Medica segment on the HHR website at www.healthworldnews.tv/streaming … MedHHR.mov once the segments begins to air in June, and

- At least 30 days of in-flight entertainment on one major national airlines in the US.

"I have every expectation that our campaign for Swiss Medica will be one of our most successful to date," said TVA Productions President Jeffery Goddard. "The successful launch of Swiss Medica's O24 Fibromyalgia(TM) pain relief solution is a story that has all the right 'ingredients' for us to create compelling, newsworthy news features that are sure to generate a massive amount of positive exposure among the 20,000-plus media outlets which receive our news feeds."

" We are very confident in the ability of this campaign to reach a massive new audience for our products, the first three days of the campaign has already resulted in a 400% increase in activity on our website. This bodes well for Swiss Medica as the media blitz campaign ramps up." Said Grant Johnson President of Swiss Medica.

Nach dem starken Abwärtstrend setzte der Kurs nach guten Nachrichten übder die MediaBlitz Kampagne ein positives Kaufsignal und stiegt am Mi. bis auf +50% an.

nun gilt es die 0.10 USD zu halten und die Konferenz sowie weitere News abzuwarten!

Swiss Medica's management will host a conference call on Monday, June 5, 2006 at 4:00 pm EST to discuss the Company's first quarter highlights and go forward strategy. Callers from the Toronto area are invited to dial 416 695-5259 at that time to participate. All other callers are invited to dial 1-877-888-4605 to participate. The conference will also be webcast with a direct link from www.swissmedica.com.

Please email questions you would like addressed during the conference call to djones@swissmedica.com.

About Emerging Markets Consulting, LLC

Emerging Markets Consulting, LLC specializes in bring little known companies to the attention of the financial community. EMC is actively focused on a carefully selected group of quality clients. EMC specializes in providing the highest level of professional service to only the most exciting companies on the market. Please visit us on the web to receive updates on our clients at emergingmarketsllc.com/index.htm

Raghu Kilambi kaufte gestern 100.000 Aktien zu 0.116 USD. Der Kurs legt heute um +30% zu!

O24 Fibromyalgia was launched in late 2005 and is the first patented, clinically tested and non-prescription product specifically for patients to fight the intense, debilitating pain caused by Fibromyalgia. The product was awarded the first ever Seal of Approval from the U.S. National Fibromyalgia Association (NFA).

O24 has been medically and clinically tested and details of those trials are available at 024zone.com/Clinicals.html.

Swiss Medica President and Chief Operating Officer Grant Johnson stated "The FDA's issuance of these certificates is coming at a perfect time. International interest in our products is growing quickly because of the science behind our products and the extraordinary efficacy of O24 for most people with pain."  

Swiss Medica to Pursue Military and International Contracts with the Appointment of Christensen Co. as Strategic Business Advisors
Monday July 17, 8:00 am ET

TORONTO, ONTARIO--(MARKET WIRE)--Jul 17, 2006 -- Swiss Medica, Inc. (OTC BB:SWME.OB - News) announced today its intention to pursue military and international contracts with the appointment of Mr. Chad Christensen, Managing Director of Christensen Co., as Strategic Business Advisor.

ADVERTISEMENT
With a distinguished career in international banking, and advisor to several Fortune 500 companies, Mr. Christensen brings to Swiss Medica a wealth of national and international contacts at all levels of business and government. He will assist the Company in its continuing development of national and international markets.

Mr. Christensen is currently serving his second term in the Nevada State Legislature. He is also a Member of the Globalization Board, George Washington University's Elliott School of International Affairs; a Member of the Transportation & Homeland Security Committees, National Conference of State Legislatures (NCSL); a Member of the Commerce and Economic Development Committee, American Legislative Exchange Council (ALEC); and is an Honorary Commander at Nellis Air Force Base (Las Vegas, Nevada).

"With Mr. Christensen's extensive knowledge and experience in navigating government and international trade agreements, he will spearhead our efforts in these areas. Swiss Medica is pleased to have Mr. Christensen join our team and open up new business opportunities for our products." said Grant Johnson, Swiss Medica's President and COO.

Mr. Christensen is a graduate of Brigham Young University, and is Managing Director of Christensen Co., an agency specializing in business development and sales management.

Grant Johnson, President and COO of Swiss Medica stated "it is our goal to have O24 used as the gold standard pain reliever within manufacturing environments where workers' safety and repetitive work strain and pain disorders are a growing concern. Medical Practitioners and consumers are telling us that they have safety concerns about oral pain relief products, especially in light of the recent study that appeared recently in the Journal of the American Medical Association. This clinical study raised concerns about people taking eight extra-strength acetaminophen tablets a day over a two week period. The study showed that 40% of the test subjects taking acetaminophen had abnormal test results that would signal liver damage, while the patients taking placebos over the same time showed no adverse liver test results".  

SierraSil is a distinct, naturally-occurring mineral composite found only in the high Sierra Mountains. SierraSil has been clinically shown to protect cartilage from breakdown and daily wear and tear by up to 73 percent and, unlike other nutraceuticals, suppresses gene expression associated with inflammatory responses.

About Sierra Mountain Minerals, Inc.

Was founded in 2003 by Peter and Michael Bentley to provide its proprietary new mineral supplement SierraSil(r) to those needing fast-acting, powerful joint and cartilage support, Sierra Mountain Minerals has experienced rapid growth in North America. Their products are available throughout the US and Canada and fine health food stores. Peter Bentley is the President of Sierra Mountain Minerals and is the Chairman of the Board of Canfor Corporation, a CDN3.7 billion revenue publicly traded forestry product company (CFP on the Toronto Stock Exchange) and also served for many years as a director of Bank of Montreal and Shell Canada Ltd. Michael Bentley, the Company's Chief Operations Officer, has held a variety of management positions at a leading forest products company. He has a Master of Science in Management from Stanford. He is also a member of the Institute of Corporate Directors and serves on a variety of business and not-for-profit boards.  

Swiss Medica Announces Caribbean Distribution Deal for O24

TORONTO, Aug. 23, 2006 (PRIMEZONE) -- Swiss Medica, Inc. (OTCBB: SWME) announced today that the Caribbean Institute of Orthopedics ("CIO") has become a Swiss Medica international distribution partner. CIO, with offices in Santo Domingo, Dominican Republican will be marketing and distributing Swiss Medica's O24 products throughout the Caribbean.

According to Kamille Ramsunder, the President of the Caribbean Institute of Orthopedics:

"We are officially endorsing Swiss Medica's award winning O24 Pain Neutralizer as our flagship pain product for this region. CIO is hoping to fight crippling diseases like Osteoarthritis/Rheumatoid Arthritis and Fibromyalgia in the most natural way and we have found that there is no better way to relieve chronic pain than to use Swiss Medica's O24 Pain Neutralizer. Swiss Medica's O24 Pain Neutralizer has also been endorsed by our partners, The Canadian Institute of Orthopedics."

Grant Johnson, President and COO of Swiss Medica stated, "We are proud to see the international orthopedic community reach out and endorse our products, and it is our goal to continue to grow Swiss Medica's international presence through these strategic distribution deals. We expect to make several more announcements regarding our international expansion plans over the next several months."

About the Caribbean Institute of Orthopedics

The Caribbean Institute of Orthopedics (CIO) supplies professional services to patients requiring orthotic devices and specialized braces for a variety of biomechanical problems for the entire Caribbean region. The Caribbean region compromises the islands of Bahamas, Barbados, Dominican Republic, Cuba, and Aruba, among others, and according to the latest United Nations survey (2004) of the Caribbean, the twenty-four island nations have a population over 38-million and a Gross Domestic Product that is growing at 2.4% a year.  

Swiss Medica Launches O24 Sampling Campaign With Golf Magazine and At Major Golf Courses

TORONTO, Aug. 24, 2006 (PRIMEZONE) -- Swiss Medica, Inc. (OTCBB:SWME) announced today that Golf Magazine has distributed over 400,000 O24 Pain Neutralizer information postcards with an attached free sample towelette as an insert to their 55+ year old magazine subscribers in the United States. The sample towelettes were included in the September 2006 issue of Golf Magazine. Golf Magazine is the world's most widely read golf publication, and is read by millions of golfers each month.

Grant Johnson, President and COO of Swiss Medica stated that "While the magazine has only been in circulation for less than a week, we are already seeing a dramatic pick-up on our www.024zone.com website and 1-877 toll-free customer care line regarding where they can buy O24."

O24 is also being sampled to over 100,000 golfers this summer at golf tournaments in Canada and in clubhouses including Angus Glen Golf Club (north of Toronto), the home to the 2007 Canadian Open PGA golf tournament.

"O24 has received an enthusiastic response from golfers who have found its strong and quick pain relief to be very effective to deal with pain and stiffness, both on and off on the Golf Course," stated Kevin Thistle, Vice President/General Manager of Angus Glen Golf Club.  

In Kürze erscheint der 25 seitige Investment Report über die Swiss medica Inc. von DEL LA RUE. Interessenten wird angeboten, den Investment Report jetzt bei DEL LA RUE vorzubestellen, da nur eine limitierte Auflage gedruckt wird.

Die kostenlose Print- oder PDF-Version jetzt über info@dellarue.de vorbestellen.
(Bei der Printversion bittet DEL LA RUE die Versandadresse mit anzugeben.)

Am 12. und 13. Sep. stellt die SwissMedica Beteiligungs- GmbH auf der Fund and Finance Messe in Köln aus. Alle Infos zur Messe und den Ausstellern/Programm unter www.fundsandfinance.de

Wir vergeben 20 Freikarten für die funds & finance Messe am 12. und 13. September in Köln.

Die funds & finance ist deutschlandweit die erste und einzige Messe, auf der alle wichtigen Marktteilnehmer der Fonds Community zusammenfinden. Neben dem Austausch mit Premium Ausstellern aus den Bereichen offener, geschlossener und alternativer Fonds, Verbänden, Fachmedien und weiteren relevanten Marktteilnehmern der Finanzbranche bietet Ihnen die funds & finance 2006 ein umfangreiches Vortragsprogramm und Podiumsdiskussionen mit Fachvorträgen renommierter Referenten aus der Finanzbranche, Medien, Verbänden und Politik.

Die Freikarten gelten für beide Messetage und umfassen ein exklusives Catering.

- Wert der Karten 45,- EURO.
- Einsendeschluss an info@dellarue.de ist Fr. der 08. September um 24.00 Uhr.

Mehr informationen auf www.dellarue.de

DEL LA RUE hat noch immer Freikarten!

Wir vergeben Freikarten für die funds & finance Messe am 12. und 13. September in Köln.

Die funds & finance ist deutschlandweit die erste und einzige Messe, auf der alle wichtigen Marktteilnehmer der Fonds Community zusammenfinden. Neben dem Austausch mit Premium Ausstellern aus den Bereichen offener, geschlossener und alternativer Fonds, Verbänden, Fachmedien und weiteren relevanten Marktteilnehmern der Finanzbranche bietet Ihnen die funds & finance 2006 ein umfangreiches Vortragsprogramm und Podiumsdiskussionen mit Fachvorträgen renommierter Referenten aus der Finanzbranche, Medien, Verbänden und Politik.

- 2-Tageskarte (12. und 13. Sep.)
- inkl. 50% Rabbat auf das exklusive catering
- Wert einer Karte: 45,- EURO.
- Einsendeschluss an info@dellarue.de ist Mo. der 11. September um 13.00 Uhr.
- Die Messe ist ausschließlich für Finanzintermediäre, nicht für Privatbesucher.

Bedenken Sie bitte, die Karten können erst am 12. Sept. bei Ihnen eintreffen.

Swiss Medica Approved by German Legal Authorities to Raise Up to 10 Million Euros Via Non-Convertible Preferred Shares

TORONTO, Sept. 11, 2006 (PRIMEZONE) -- Swiss Medica, Inc. (OTCBB:SWME) is pleased to announce that Swiss Medica GmbH, a German privately held company, has fulfilled all legal obligations under the laws of Germany and has been approved to raise up to 10 million Euros in gross proceeds via a prospectus offering. These funds will be used to invest into non-convertible preferred shares of Swiss Medica, Inc. at a price of 1.25 euro per preferred share.

The preferred shares are not convertible into publicly traded common shares of Swiss Medica, Inc. and will have a dividend yield of 16 percent. The preferred shares cannot be redeemed prior to December 31, 2008 and mature on December 31, 2011.

Information on Swiss Medica GmbH is only available in German at www.swissmedica.de/

Raghu Kilambi, Swiss Medica's CEO, noted, "While this regulatory approval took longer than expected, we feel that the structure of this proposed financing provides much long-term flexibility for Swiss Medica Inc. as it grows its North American and international businesses. Swiss Medica Inc. plans to use proceeds of this financing to fund its growth including working capital investment, sales/marketing and debt reduction."

German individual and institutional investors are expected to invest in this financing, which will have multiple closings over the next several months.

The subject of the German regulatory approval by the BaFin is only that the offer includes formally all information required under the laws of Germany for this kind of offering but not that the contents of the offering are true or that the contents have been controlled by BaFin.

The information contained herein does not constitute or form part of an offer or solicitation of an offer to purchase or subscribe for securities for sale in the United States and Canada. The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933, as amended and may not be offered or sold in the United States unless registered or pursuant to an exemption from such registration. No public offering of securities is being made in the United States.  

Swiss Medica Announces South Africa Distribution Deal for O24

TORONTO, Sept. 14, 2006 (PRIMEZONE) -- Swiss Medica, Inc. (OTCBB:SWME) announced today that Heritage Healthcare of the Republic of South Africa has become Swiss Medica's latest international distribution partner. Heritage Healthcare will be marketing and distributing Swiss Medica's O24 products throughout South Africa ("SA").

Heritage Healthcare will be commencing a national marketing campaign which will include promoting 024 into the major pharmacy chains and distributors and sampling the 024 products to orthopedic surgeons, physiotherapists and pain management specialists in South Africa.

According to Gary Schach, Founder of Heritage Healthcare:

"South Africans are sports crazy and many suffer from pain caused by over-doing activities whilst participating in soccer, rugby, athletics, tennis, running and golf. I personally have 26 years experience in developing, manufacturing and marketing healthcare and surgical products to the SA market and feel certain that 024 will soon become a leading contender in the natural product pain relief sector in South Africa."

Grant Johnson, President and COO of Swiss Medica, stated, "We are proud to see the international healthcare community recognize and support the strengths of our brands: all-natural, clinically-tested products that provide fast, safe and effective relief. It is our goal to continue to grow Swiss Medica's international presence through these strategic distribution deals. We expect to make several more announcements regarding our international expansion plans over the next several months."

About the Heritage Health

Heritage Healthcare is a division of Heritage Surgical Products cc of South Africa who is an innovative leader in the manufacture and supplier of unique, high quality urological, incontinence, surgical and medical products servicing the South African marketplace. Heritage Healthcare has a strong and respected relationship with many healthcare professionals, pharmacists and allied professionals throughout South Africa. The Republic of South Africa has a population of 42.4 million, a Gross Domestic Product in 2005 of $570 Billion (18th highest Worldwide) and a per capita income of $12,160 (54th highest in the world).  

(19.09.06) Laut inernen Informationen wird Yokes Foods (13 Filialen) innerhalb der nächsten Wochen, PMS Escape einführen.

Quelle:www.dellarue.de  

Swiss Medica is Ranked No. 3 in PROFIT Magazine's HOT 50 Canadian Emerging Growth Companies

TORONTO, Sept. 19, 2006 (PRIMEZONE) -- Swiss Medica, Inc. (OTCBB:SWME) is pleased to announced that it has been ranked No. 3 in the top 50 emerging growth companies in Canada according to the 7th annual PROFIT HOT 50 ranking. The PROFIT HOT 50 is the definitive ranking of Canada's emerging growth companies and is published in the October 2006 issue of "PROFIT: Your Guide to Business Success" and online at www.PROFITguide.com. The PROFIT HOT 50 ranks young firms by two-year revenue growth.

According to Ian Portsmouth, editor of PROFIT, "The PROFIT HOT 50 companies represent the ambition, sophistication and immense contribution of Canada's entrepreneurial sector. PROFIT is proud to celebrate the success of these businesses and to share their growth strategies."

"I am extremely grateful to our employees, customers, shareholders and other stakeholders who have supported our vision of commercializing elite over-the-counter, patented all natural products for chronic ailments. We believe that we are still very early in the product acceptance cycle for science-based over-the-counter products for chronic ailments and increasing concerns about side effects from prescription drugs will allow Swiss Medica's patented products to continue to gain significantly more acceptance from consumers and the medical community in North America and throughout the world," said Raghu Kilambi, CEO of Swiss Medica Inc.

About PROFIT: Your Guide to Business Success

PROFIT: Your Guide to Business Success, offers news, strategies, tips, interviews and other recourses to the CEOs of Canadian growth companies. Each year, PROFIT, which currently reaches more than 370,000 readers nationally, hosts a number of events that bring together business leaders in the fast-growth segments and champions the interests of those leaders. PROFIT was founded in April 1982 as Canada's first national magazine geared to entrepreneurs. Visit PROFITguide.com.  

Heute wurde baknnt das SWME einen Reverse Stock Split durchführen wrid.
Voraussichtlich dürfte das durchgehen, in einem Verhältnis von bis zu 1 : 10!

Das Unternehmen stellt seine Weichen, so wurde am 4. September bekannt, dass die BaFin den Verkaufsprospekt der swissmedica Beteiligungs GmbH über Genussrechtskapital an der swissmedica Inc. genehmigte. Auf der anschließende Investorenmesse am 12. und 13. September in Köln konnte sich das Unternehmen erstmals deutschen Investoren präsentieren und Geschäftskontakte knüpfen.

Auch wir sehen in der Unternehmensbeteiligung an der swissmedica Inc. über Genussrechtskapital eine attraktive Alternative zur Aktienanlage. Zudem erhält die swissmedica Inc. dadurch die für Wareneinkäufe und Marketingkampagnen nötigen finanziellen Mittel.


Den Investment Report  über die swissmedica Inc. erhalten Sie online unter www.dellarue.de/Report.html

Haben Sie Interesse am Verkaufsprospekt über die Genussrechtsbeteiligung an der swissmedica Inc., mit einer Verzinsung von 9,5% p.a. auf einer Laufzeit von mindestens 2 und maximal 5 Jahre, wenden Sie sich bitte an info@dellarue.de, wir schicken Ihnen dann umgehend den Prospket per Hauspost zu.

Weitere Informationen über das DEL LA RUE – Investment Team und unsere Investmentideen finden Sie unter www.dellarue.de.

Eine Übersicht der letzten Meldungen:


(21.09.06) Swiss Medica wird voraussichtlich ein Reverse Stock Split in einem Verhältnis von bis zu 1 : 10 durchführen.

(21.09.06) Hillers Supermarket aus Michigan (6 Filialen) führt demnächst PMS Escape ein.

(19.09.06) Swiss Medica landet auf Platz 3. der besten kanadischen Newcomer-Firmen.

(19.09.06) Laut inernen Informationen wird Yokes Foods (13 Filialen) innerhalb der nächsten Wochen, PMS Escape einführen.

(14.09.06) Swiss Medica Inc. verkündet Absatzvertrag mit Heritage Healthcare für Südafrika.

(12.09.06) Die Supermarktkette "Big Y" (53 Filialen) wird laut internen Informationen demnächst PMS Escape einführen.

(11.09.06) Presseberich der Swiss Medica Inc. über die Zulassung des Verkaufsprospekts.

(05.09.06) Der Prospekt für die Genussrechte der swissmedica Beteiligungs- GmbH wurde genehmigt.

(03.09.06) Die swissmedica Inc. ist am 12. und 13. September auf der funds & finance Messe in Köln.

28.10.06 - Verzögerung: Big Y führt PMS Escape von swissmedica erst im November ein.

Quelle: www.dellarue.de/Insider.html

Hallo SwissMedica-Fans

auf www.dellarue.de können kostenlose Produktproben von SwissMedica (024 Fibromyalgia und 024 Pain Neutralizer) sowie der aktuelle Investment Report über das Unternehmen bestellt werden.

Sorgenkind "swissmedica"
DEL LA RUE - Investmentbrief
23.11.2006 www.dellarue.de/Ausgabe.html

Die swissmedica Inc. ist derzeit unser Sorgenkind. Nach wie vor sind wir von den Produkten und dem Management überzeugt, dennoch gelang in diesem Jahr noch nicht der erhoffte Durchbruch.

Vor kurzem wurden die Zahlen für das dritte Quartal veröffentlicht. Die Umsätze lagen mit 349 TUSD unter unseren Erwartungen. Zusätzlich gab eine große Supermarktkette die Patch Box zurück, was einen Gegenwert von 217 TUSD ausmachte. Unter dem Strich fuhr das Unternehmen im dritten Quartal einen Verlust von 1,8 Mio. USD ein.


Hoffnung gibt die vor einigen Monaten gegründete NAPI Inc., die sich auf den Vertrieb der Produkte an Kliniken und Ärzte konzentriert. In diesem Segment sollen deutliche Zuwächse erkennbar sein. Es ist daher anzunehmen, das der zukünftige Absatzmarkt für swissmedica wohl dochnicht in den großen amerikanischen Supermärkten liegt, sondern vielmehr im Vertrieb über Kliniken und Ärzte.

Der Kurs gab nach der Bekanntgabe der Quartalszahlen nur gering nach, da diese wohl schon im Kurs Eingpreist waren. Mit einer Marktkapitalisierung von 2,5 Mio. € liegt das Unternehmen im Jahrestief. Es ist daher anzunehmen, dass der Kurs auf Nachrichten stark reagieren wird. Wir raten Anlegern daher den Kurs und Newsflow zu beobachten.

Swissmedica hat derzeit eine Marktkap. von 900 TUSD, bei Umsätzen von 6 Mio. 2005 und ca. 2 Mio. 2006. Alles hängt davon ab, wie es weitergeht.


DEL LA RUE - investment Brief
www.dellarue.de

Zocker-TIPP


Noch vor einem Jahr gehörte die swissmedica Inc. zu einem stark wachsenden Unternehmen im Vertrieb von patentierten, klinisch getesteten und natürlichen Produkten gegen Schmerzen. Spezialisiert auf den Vertrieb der eigenen Produkte über Einzehandelsketten, musste das Unternehmen 2006 starke Umsatzeinbrüche hinnehmen. Derzeit befindet sich das Unternehmen laut eigener Aussage in der Reorganisation.

Hohe Werbekosten für den hiesigen US-Markt verschlangen fast die gesamten Umsatzerlöse. Daher wundert es kaum, dass trotz einer 70-80 % Gewinnmarge die Profitabilität ausblieb. Zudem gelang es nicht, die Nischenprodukte wie 024 Fibromyalgia™ stark genung über den Einzehlandel zu vertreiben. Trotz der steigenden Kundennachfrage war der Umsatz für Für den Einzelhandel zu gering. Die Folge waren Produktrückgaben. Als vertriebsstark erwies sich dagegen die North American Phyisicians Inc.(kurz: NAPI). Die NAPI vertreibt die Produkte der swissmedica Inc. über Ärzte und Kliniken. Im letzten Geschäftsjahr steiß sie dabei auf große Nachfrage. Die Umsätze über die NAPI konnten kontinuierlich gesteigert werden. In diesem Geschäftsmodell dürfte auch die Zukunft für die angeschlagene swissmedica Inc. liegen.

Gelingt es dem Unternehmen neue Investoren an Land zu ziehen und das Geschäftsmodell in diese Richtung zu lenken, könnte das Unternehmen die drohende Insolvenz abwehren und zu neuem Glanz erscheinen.

Für Zocker scheint die Aktie beim derzeitigen Kursniveau äußerst interessant zu sein. Eine Nachricht über eine erfolgreiche Neuausrichtung dürfte zu einem enormen Kursanstieg führen.  

Letzte Woche war seit langem wieder ein Lebenszeichen von der swissmedica zu sehen. Die Sanierung scheint voranzuschreiten. So war die swissmedica Beteiligungs GmbH auf der Salzburger Finanzmesse (video unter www.swissmedica.de).

Kann die Beteiligungs die nötigen Finanziellenmittel auftreiben und SWME eine neuausrichtung gelingen, dürften wir bald wieder alte Kurse sehen, das heisst Kurs weiter über akuell von 0.008 USD, sonder sehen 0.08 oder 0.18!

ohne gewähr

Swiss Medica recognized that the national pharmacy retail channel is not the most appropriate channel in the United States for O24 whose unique patent and clinical/medical trials need to be explained in detail in formats such as the 1 hour branded radio shows that were successful in Canada, but are not as available in the United States. In addition O24's efficacy can be best proven by using a towelette sample of O24.

The USA direct-to-consumer marketplace is the most developed and elaborate in the world, allowing manufacturers many means to bypass retailers and access consumers directly. Swiss Medica is working to launch the distribution of O24 with a major USA-based direct-to-consumer marketing organization which focuses on marketing products through mailing samples of products to the millions of customers in their database and then auto-shipping regular orders of products to customers who opt-into the re-order program. This company chose O24 after an extensive product due diligence process and has estimated that it can build a large regular direct order business for a private label O24 due to the extremely high efficacy and customer satisfaction after the use of a single compact O24 towelette. Another pain relief product distributed by the same company experienced initial demand that translated in several million dollars of annualized wholesale revenues to the manufacturer.

The direct-to-consumer channel is much more attractive to Swiss Medica due to lower investments in upfront inventory, better payment terms from direct- to-consumer marketing partners and no need to spend consumer marketing dollars in the United States.

Nach Monate langer Ruhe dachten schon viele es sei vorbei mit der Swissmedica.
Dann gab es frisches Kapital und nun neue Pläne zur Neuausrichtung.
Der Kurs stieg seither um 300% von 0.005 auf bis 0.02 USD:
Das sind aber immernoch erst 2 Mio. Kapitalisierung.

Nun geht es darum wie das Comeback anläuft und wie das Potential aussieht im Lizensierungsgeschäft!

die 200 Tage-Linie hält und dient nun als Support.
Warten auf News ist angesagt.
Bs dahin genießen wir das erneute Kursplus

Das Teil gibt es doch garnicht mehr.nicht mehr handelbar
Was machst Du hier?
Pleite?
Machst SM schöne Augen?
Odda issa einfach voll?
hm ,aber toll macht er das!

Hallo! hat noch jemand Anteile von Swiss Medica Inc? Mal schauen, wer noch eine Meinung zu SWE haben wird.Würde mich freuen,wenn auch noch andere Leidensgenossen sich hier mal melden würden OK!